Intercept Pharmaceuticals has announced plans for the first ever pivotal trial in non-alcoholic steatohepatitis (NASH), setting a high bar for a growing pipeline of drugs against the liver disease.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Chi, K. The NASH drug dash. Nat Rev Drug Discov 14, 447–448 (2015). https://doi.org/10.1038/nrd4667
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4667
This article is cited by
-
Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists
Cell Biology and Toxicology (2021)
